October 12, 2022"Building a multi-level R&D system and actively creating a second growth curve" is the development strategy of the company, and also one of the key tasks of the company in the next few y...view
March 22, 2024Recently, Beilu Pharmaceutical received the "Drug Supplementary Application Approval Notice" (Notice Number: 2024B01144) for Gadobenate Dimeglumine Injection issued by the National Medical P...view
February 1, 2023Recently, Beijing Beilu Pharmaceutical Co., Ltd. was once again awarded the title of "Class A Unit for Safety Production" in Miyun Park of Zhongguancun District. The company has won this awa...view
July 27, 2021Recently, our company received the“Drug Supplementary Application Approval Notice”(Notice Number: 2021B02267, 2021B02268) for two specifications of Gadopentetate Dimeglumine Injection.view
December 1, 2023The flagship product, Jiuwei Zhenxin Granules, a central nervous system medication developed by Beilu Pharmaceutical, has been included in the "Guidelines for the Diagnosis and Treatment of Ankyl...view